NeuroPointDX has developed a new diagnostic tool for autism spectrum disorder (ASD).
Help your patients receive an earlier autism diagnosis. The NeuroPointDX Autism Spectrum Disorder (NPDX ASD) test, developed for children 18 – 48 months old, is a blood panel that identifies metabolic subtypes (or metabotypes) associated with ASD. It can identify about 30% of children with autism and help your patients receive a diagnosis and begin treatment sooner.
Our clinical study on autism funded by the National Institutes of Mental Health (NIMH) was performed using fasting blood plasma samples from patients 18-48 months old. Test performance has not been evaluated in patients younger than 18 months or older than 48 months of age.
Who should get the NPDX ASD test for autism?
The test is appropriate for a child who:
- Has failed screening for developmental milestones indicating risk for ASD (e.g., Modified Checklist for Autism in Toddlers (M-CHAT), ASQ-3, Parents’ Evaluation of Developmental Status (PEDS), Screening Tool for Autism in Toddlers and Young Children (STAT), etc.).
- Has a family history, such as a sibling diagnosed with ASD.
- Has an ASD diagnosis for whom additional metabolic information may provide insight into the child’s condition and therapy.